마이코플라스마 검사 시장 : 제품 유형별, 기술별, 용도별, 최종 용도별, 예측(2024-2032년)

Mycoplasma Testing Market size is expected to grow at over 11.9% CAGR during 2024-2032, driven by increasing prevalence of mycoplasma contamination in cell culture-based research and the strong need for biopharmaceuticals and vaccines. The growing demand for biopharmaceuticals and vaccines is a significant driver propelling the market expansion. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, are becoming the cornerstone of modern medicine. As per WHO, in 2021 alone, the global supply of vaccines amounted to 16 billion doses, valued at approximately US$ 141 billion.

As biopharmaceuticals and vaccines are manufactured using complex cell culture processes, ensuring their safety and efficacy has turned paramount. Mycoplasma contamination poses a serious risk to the quality and safety of these products. Contaminated biopharmaceuticals and vaccines can lead to adverse effects on patients, regulatory issues, and financial losses for manufacturers. To meet regulatory requirements and maintain product quality, biopharmaceutical and vaccine manufacturers are increasingly investing in advanced mycoplasma testing solutions. These solutions enable rapid and accurate detection of mycoplasma contamination while helping to safeguard the integrity of biopharmaceutical and vaccine production processes.

The mycoplasma testing market is classified based on product type, application, technique, end-use and region.

The market size from the instruments product type segment is expected to grow substantially at 11.8% CAGR from 2024 to 2032. Advanced instrumentation technologies, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) offer rapid and accurate detection of mycoplasma contamination in cell cultures and biopharmaceutical products. These instruments enable high-throughput screening and automation, enhancing efficiency and productivity in mycoplasma testing laboratories. Additionally, the advent of innovative portable instruments facilitates on-site testing, further reducing turnaround times and enabling real-time monitoring of contamination risks.

By technique, the mycoplasma testing industry from the enzyme-linked immunosorbent assay (ELISA) segment is poised to record 11.8% CAGR through 2032. ELISA-based assays leverage the specificity of antigen-antibody interactions to detect and quantify mycoplasma antigens or antibodies in biological samples. With its high sensitivity and scalability, ELISA also offers a cost-effective solution for routine mycoplasma screening in research laboratories and biopharmaceutical manufacturing facilities.

Asia Pacific mycoplasma testing industry is set to expand at 12.3% CAGR till 2032, driven by rapid industrialization, increasing investments in biopharmaceutical R&D, and the growing awareness about product safety and quality standards. Countries, such as China, India, and Japan are witnessing a surge in biopharmaceutical manufacturing activities, fueled by favorable government initiatives, infrastructure development, and technological advancements. Moreover, the presence of a large pool of skilled labor and cost-effective manufacturing capabilities will further augment the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advancements in cell culture technology
    • 3.2.1.2 Rising cell culture contamination
    • 3.2.1.3 Increasing research and development activities
    • 3.2.1.4 Increasing demand for fast, accurate, and affordable mycoplasma testing
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Long and laborious detection process
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Kits and reagents
  • 5.3.1 PCR (Polymerase chain reaction) assays
  • 5.3.2 Nucleic acid detection kits
  • 5.3.3 Stains
  • 5.3.4 Elimination kits
  • 5.3.5 Standards & controls
  • 5.3.6 ELISA (Enzyme-linked immunosorbent assay) kits
  • 5.3.7 Other kits and reagents
• 5.4 Services

Chapter 6 Market Estimates and Forecast, By Technique, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 PCR (Polymerase chain reaction)
• 6.3 ELISA (Enzyme-linked immunosorbent assay)
• 6.4 Microbial culturing technique
• 6.5 Enzymatic methods
• 6.6 Other techniques

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cell line testing
• 7.3 Virus testing
• 7.4 End of production cells testing
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Academic research institutes
• 8.3 Cell banks & laboratories
• 8.4 Contract research organizations
• 8.5 Pharmaceutical & biotechnology companies
• 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Becton, Dickinson, and Company (BD)
• 10.2 Bio-Rad Laboratories, Inc.
• 10.3 Charles River Laboratories International, Inc.
• 10.4 Creative Bioarray
• 10.5 Eurofins Scientific
• 10.6 InvivoGen
• 10.7 Lonza Group AG
• 10.8 Merck KGaA
• 10.9 Minerva Biolabs GmbH
• 10.10 PromoCell GmbH
• 10.11 QIAGEN N.V.
• 10.12 Sartorius AG
• 10.13 Thermo Fisher Scientific Inc.